Document Detail


Treatment of severe intermittent claudication by controlled defibrination.
MedLine Citation:
PMID:  66429     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifteen patients with severe intermittent claudication were treated by therapeutic defibrination with subcutaneous injections of ancrod for 5 weeks. Mean plasma-fibrinogen was maintained below 50% of the initial value throughout the treatment period. This reduction in plasma-fibrinogen was accompanied by a parallel fall in whole-blood viscosity and a pronounced clinical improvement. Objective measurements showed maximum benefit on the 21st day of treatment, when the mean resting ankle/arm pressure index had increased by 37%, the post-exercise pressure index had increased by 50%, and the time taken for the pressure index to return to a resting value after a constant exercise had decreased by 33%. (The claudication-count had increased by 59%).
Authors:
J A Dormandy; K B Goyle; H L Reid
Related Documents :
7785009 - Maximal values of sniff nasal inspiratory pressure in healthy subjects.
8617069 - Energy metabolism of thoracic surgical patients in the early postoperative period. effe...
16151839 - Non-invasive assessment of human large vein diameter, capacity, distensibility and elli...
18251439 - The effect of body position on inspiratory airflow in divers.
23875249 - Effect of beta-aescin extract from chinese buckeye seed on chronic venous insufficiency.
15233839 - Intermittent venous compression, and the duration of hyperaemia in the common femoral a...
17061929 - Influence of age, body mass index, and blood pressure on the carotid intima-media thick...
1269259 - On-line computer processing of pressure data from cardiac catheterizations.
1484369 - Primary effects of carotid chemoreceptor stimulation on gracilis muscle and renal blood...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1977 Mar 
Date Detail:
Created Date:  1977-05-12     Completed Date:  1977-05-12     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  625-6     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ancrod / administration & dosage,  pharmacology,  therapeutic use*
Blood Viscosity / drug effects
Drug Evaluation
Endopeptidases / therapeutic use*
Fibrinogen / antagonists & inhibitors
Follow-Up Studies
Humans
Injections, Subcutaneous
Intermittent Claudication / blood,  drug therapy*
Chemical
Reg. No./Substance:
9001-32-5/Fibrinogen; EC 3.4.-/Endopeptidases; EC 3.4.21.-/Ancrod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Post-thyroidectomy hypocalcaemia: A feature of the operation or the thyroid disorder?
Next Document:  Heart-rate variability in brain-damaged adults.